SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
-4.76%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$1.85B
AUM Growth
+$1.85B
(-1.1%)
Cap. Flow
+$57.9M
Cap. Flow
% of AUM
3.13%
Top 10 Holdings %
Top 10 Hldgs %
47.07%
Holding
109
New
9
Increased
31
Reduced
10
Closed
22
Top Buys
| 1 |
Microsoft
MSFT
|
$68.9M |
| 2 |
Chipotle Mexican Grill
CMG
|
$37.4M |
| 3 |
Amazon
AMZN
|
$37.1M |
| 4 |
Advanced Micro Devices
AMD
|
$33.5M |
| 5 |
Royalty Pharma
RPRX
|
$28.5M |
Top Sells
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$67.2M |
| 2 |
XYZ
Block, Inc.
XYZ
|
$28.8M |
| 3 |
TSMC
TSM
|
$23.9M |
| 4 |
Accenture
ACN
|
$21.6M |
| 5 |
Canadian Pacific Kansas City
CP
|
$20.9M |
Sector Composition
| 1 | Healthcare | 62.92% |
| 2 | Consumer Discretionary | 12.25% |
| 3 | Technology | 11.13% |
| 4 | Communication Services | 4.55% |
| 5 | Industrials | 3.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
KalVista Pharmaceuticals
KALV
$713M
| $23.3M | 1.26% |
2,420,851
+386,345
| +19% | +$3.72M |
|
27
RH
RH
$4.14B
| $21.4M | 1.16% |
80,989
-2,200
| -3% | -$582K |
|
28
Eli Lilly
LLY
$661B
| $21M | 1.13% |
+39,100
| New | +$21M |
|
29
Sutro Biopharma
STRO
$85.6M
| $20.4M | 1.1% |
5,883,693
| – | – |
|
|
BCYC
30
Bicycle Therapeutics
BCYC
$492M
| $20.3M | 1.1% |
+1,010,976
| New | +$20.3M |
|
31
Zura Bio
ZURA
$132M
| $18.8M | 1.02% |
2,850,000
| – | – |
|
32
Boston Scientific
BSX
$159B
| $18.7M | 1.01% |
353,741
+335,500
| +1,839% | +$17.7M |
|
33
ProKidney
PROK
$319M
| $17.7M | 0.96% |
3,867,843
+674,668
| +21% | +$3.09M |
|
34
Capital One
COF
$142B
| $17.6M | 0.95% |
181,660
-16,910
| -9% | -$1.64M |
|
35
Wells Fargo
WFC
$258B
| $17.5M | 0.95% |
428,506
+5,000
| +1% | +$204K |
|
36
Apollo Global Management
APO
$75.9B
| $17.2M | 0.93% |
+191,900
| New | +$17.2M |
|
37
Hilton Worldwide
HLT
$64.7B
| $17.1M | 0.92% |
113,962
-900
| -0.8% | -$135K |
|
38
InflaRx
IFRX
$117M
| $17.1M | 0.92% |
5,733,910
| – | – |
|
39
McKesson
MCK
$85.9B
| $16.3M | 0.88% |
37,540
+35,710
| +1,951% | +$15.5M |
|
40
Johnson & Johnson
JNJ
$429B
| $14M | 0.76% |
90,097
+7,297
| +9% | +$1.14M |
|
41
UnitedHealth
UNH
$279B
| $13.7M | 0.74% |
27,223
+14,400
| +112% | +$7.26M |
|
42
Sana Biotechnology
SANA
$759M
| $11.5M | 0.62% |
2,963,704
+849,904
| +40% | +$3.29M |
|
43
Agios Pharmaceuticals
AGIO
$2.36B
| $11.2M | 0.61% |
454,000
| – | – |
|
44
Arcus Biosciences
RCUS
$1.24B
| $10.7M | 0.58% |
+597,099
| New | +$10.7M |
|
|
MREO
45
Mereo BioPharma
MREO
$275M
| $9.5M | 0.51% |
7,364,438
| – | – |
|
46
AnaptysBio
ANAB
$630M
| $8.61M | 0.47% |
+479,445
| New | +$8.61M |
|
47
Kezar Life Sciences
KZR
$28.5M
| $8.53M | 0.46% |
716,759
| – | – |
|
48
Alvotech
ALVO
$2.48B
| $8.47M | 0.46% |
928,402
-71,598
| -7% | -$653K |
|
49
Sanofi
SNY
$122B
| $6.22M | 0.34% |
116,041
| – | – |
|
50
Elanco Animal Health
ELAN
$8.62B
| $6.03M | 0.33% |
536,500
+99,600
| +23% | +$1.12M |
|